All News

8 February 2011

Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian CancerAntibodies

7 February 2011

Helix BioPharma Corp. Receives FDA IND Approval to Conduct a U.S. Phase I Clinical Study With Its Lung Cancer Drug Candidate L-DOS47Antibodies

4 February 2011

Journal of Clinical Oncology Publishes Clinical Trial Results of VELCADE Combination in Aggressive Subtypes of Non-Hodgkin LymphomaAntibodies

4 February 2011

Enbrel (etanercept) Significantly Improved Scalp Involvement in Patients with Moderate to Severe Plaque PsoriasisAntibodies

3 February 2011

AVEO Pharmaceuticals Receives USAN Name for Novel, Internally Discovered Anti-HGF/c-MET Pathway AntibodyAntibodies

2 February 2011

Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of NecitumumabAntibodies

1 February 2011

APEIRON ACQUIRES RIGHTS FOR A PHASE II BIOLOGIC AGAINST NEUROBLASTOMA AND OTHER CANCERS FROM MERCK KGAA, GERMANYAntibodies

31 January 2011

Peregrine Completes Patient Enrollment in Phase Ib HCV/HIV Coinfection TrialAntibodies

31 January 2011

FDA Approves Rituxan for First-Line Maintenance Use in Follicular LymphomaAntibodies

31 January 2011

MorphoSys Reaches Clinical Milestone with PfizerAntibodies

25 January 2011

Oxford BioTherapeutics Out-Licenses Therapeutic Antibody for the Treatment of Solid CancersAntibodies

25 January 2011

Emergent BioSolutions Announces Initiation of Phase Ib/II Study of TRU-016 in Combination with Bendamustine for Chronic Lymphocytic LeukemiaAntibodies

25 January 2011

Radient Pharmaceuticals’ Wholly-Owned Subsidiary NuVax Therapeutics Signs Exclusive License Agreement for Immune-Gene Therapeutics Technology From University of Florida Research CenterAntibodies

24 January 2011

MorphoSys Announces Clinical Milestone within Boehringer Ingelheim AllianceAntibodies

24 January 2011

Spectrum Pharmaceuticals Submits Data to FDA in Support of Bioscan Removal for ZEVALINAntibodies

24 January 2011

Immunomedics Reports First Experimental Studies Combining Antibody-Drug Conjugate With Antibody-Directed Radiation Therapy for Pancreatic CancerAntibodies

21 January 2011

Immunomedics Reports Targeted Therapy for Advanced Pancreatic Cancer Improves SurvivalAntibodies

21 January 2011

YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI SymposiumAntibodies

21 January 2011

FibroGen Reports Interim Results of a Phase 1 / 2 Trial of FG-3019 in Locally Advanced or Metastatic Pancreatic CancerAntibodies

21 January 2011

NewLink Genetics to Present Phase 2 Data of Its HyperAcute Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers SymposiumAntibodies

20 January 2011

Investigational Compound Offers Novel Anti-IGF Approach To Inhibit Growth of Cancer CellsAntibodies

19 January 2011

Theraclone and Pfizer Enter into Infectious Disease and Cancer Antibody Discovery CollaborationAntibodies

19 January 2011

Merck Serono: Erbitux Long-Term Survival Benefit for mCRC Patients Confirmed With FOLFOXAntibodies

19 January 2011

Peregrine Announces Initiation of Investigator-Sponsored Trial in HER2-Negative Metastatic Breast CancerAntibodies

18 January 2011

MENTRIK Biotech, LLC Acquires Fc Engineered, High Affinity, Fully Humanized Anti-CD20 Antibody (AME-133v)Antibodies

18 January 2011

Regeneron and Bayer Start Phase 3 Trial to Extend Ophthalmology Research & Development Program for VEGF Trap-Eye in AsiaAntibodies

17 January 2011

DiaMedica Announces New Data With Its Novel Monoclonal Antibody ProgramAntibodies

12 January 2011

Sandoz announces phase II clinical trial for biosimilar version of leading monoclonal antibody rituximabAntibodies

12 January 2011

FibroGen Announces the Initiation of an Open-label Phase 2 Study to Evaluate the Safety and Efficacy of FG-3019 in Individuals with Idiopathic Pulmonary FibrosisAntibodies

12 January 2011

MedImmune and Micromet Announce Initiation of Phase 1 Trial of the CEA BiTE Antibody MEDI-565 (MT111) in Patients with Advanced Gastrointestinal CancersAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

TSLP Pipeline Review

Aflibercept (Eylea) Biosimilars Pipeline Review

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Her3-Targeted Immunotherapy Pipeline Review

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

CD73 Inhibitor Pipeline Review